People with pre-existing chronic kidney disease (CKD) may have naturally elevated carnitine levels and need careful assessment before treatment
26(9): 95761 Zhang AQ, Mitchell SC, Smith RL
Real-time benefit tools are now required in Medicare Part D to inform prescribers of patient-specific drug costs, but their effectiveness depends on clinician use and patient engagement in cost discussions [136]
GLP-1 agonists are not expensive to produce, however, and the patent on Ozempic expired in January of 2026 in Canada and China (and lasts until 2030 in the U.S.), but I expect the market to bring the costs down dramatically over the next few years
If the solution appears cloudy, discolored, or contains particles when it should be clear, the medication has likely been compromised and should not be used
Nurse Felicia came in next and went above and beyond to answer my additional questions with honesty and integrity, which I greatly appreciated